NEWS RELEASES
The information contained in each news release on this page was factually accurate on the date it was issued and posted.
Sutro Biopharma to Present Updated Clinical Data for its STRO-002 Antibody-Drug Conjugate at the AACR Virtual Annual Meeting on April 27, 2020
- Company to host a conference call following the presentation - SOUTH SAN FRANCISCO, Calif., April. 13, 2020 – Sutro Biopharma, Inc. (NASDAQ: STRO), today announced that the company has been invited to present updated clinical data from its STRO-002 antibody-drug...
SutroVax Announces $110M Series D Financing to Advance Broadest-Spectrum Pneumococcal Vaccine Candidates to Prevent Pneumonia
Foster City, CA, March 26, 2020 – SutroVax, a biopharmaceutical company dedicated to the delivery of superior and novel vaccines designed to prevent or treat some of the most common and deadly infectious diseases worldwide, today announced the closing of a $110...
Sutro Biopharma Reports Full Year 2019 Financial Results and Recent Business Highlights and Developments
STRO-002 Data from an Ongoing Phase 1 Clinical Trial in Ovarian and Endometrial Cancers Late-Breaking Abstract was accepted by AACR; Sutro plans to announce updated data in second quarter 2020 STRO-001 Phase 1 Clinical Trial and Dose Escalation Ongoing in Multiple...
Sutro Biopharma Announces Extension of First Cytokine Derivative Research Program Under Collaboration with Merck
SOUTH SAN FRANCISCO, Calif., March. 12, 2020 – Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation oncology...
Sutro Biopharma to Present Innovative Cancer Therapy Approach Using Precise Tumor Targeted Immunostimulants at World ADC London
SOUTH SAN FRANCISCO, Calif., March. 4, 2020 – Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation oncology...
Sutro Biopharma to Present at the Cowen and Company 40th Annual Health Care Conference
SOUTH SAN FRANCISCO, Calif., Feb. 27, 2020 – Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation oncology...
Sutro Biopharma Expands Senior Management Team with the Appointments of Vice President of Immunobiology and Vice President of Business Development
SOUTH SAN FRANCISCO, Calif., Feb. 5, 2020 – Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation oncology...
Sutro Biopharma to Present at 38th Annual J.P. Morgan Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Jan. 8, 2020 – Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation oncology...
Sutro Biopharma Appoints James Panek to Board of Directors
SOUTH SAN FRANCISCO, Calif., Jan. 8, 2020 – Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation oncology...
Sutro Biopharma to Participate in the 31st Annual Piper Jaffray Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Nov. 26, 2019 – Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation oncology...
